# Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

> **NCT07671560** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Qiming Wang** · enrollment: 80 (estimated)

## Conditions studied

- ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib

## Interventions

- **DRUG:** Combined group of ensatinib and arotinib

## Key facts

- **NCT ID:** NCT07671560
- **Lead sponsor:** Qiming Wang
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671560, "Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*